AR109376A1 - FORMULATIONS OF MODIFIED LIBERATION G-HYDROXIBUTY - Google Patents
FORMULATIONS OF MODIFIED LIBERATION G-HYDROXIBUTYInfo
- Publication number
- AR109376A1 AR109376A1 ARP170102053A ARP170102053A AR109376A1 AR 109376 A1 AR109376 A1 AR 109376A1 AR P170102053 A ARP170102053 A AR P170102053A AR P170102053 A ARP170102053 A AR P170102053A AR 109376 A1 AR109376 A1 AR 109376A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- hydroxibuty
- modified
- liberation
- modified liberation
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones de liberación modificada de g-hidroxibutirato. Usos terapéuticos.Modified release formulations of g-hydroxybutyrate. Therapeutic uses.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365812P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109376A1 true AR109376A1 (en) | 2018-11-28 |
Family
ID=64499936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102053A AR109376A1 (en) | 2016-07-22 | 2017-07-21 | FORMULATIONS OF MODIFIED LIBERATION G-HYDROXIBUTY |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR109376A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
-
2017
- 2017-07-21 AR ARP170102053A patent/AR109376A1/en unknown
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37341A (en) | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS | |
| AR109376A1 (en) | FORMULATIONS OF MODIFIED LIBERATION G-HYDROXIBUTY | |
| CL2018001202A1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses. | |
| CY1124595T1 (en) | ADJUSTMENT OF SUPPLEMENT ACTIVITY | |
| DK3439635T3 (en) | FORMULATIONS FOR THE TREATMENT OF FIXED TUMOR | |
| ECSP17023281A (en) | MK2 INHIBITORS AND THEIR USES | |
| CL2017001289A1 (en) | Fused bicyclic compounds, their compositions and their use for the treatment of diseases related to the modulation of the x-farnesoid receptor (fxr). | |
| CO2017002532A2 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| ECSP15043696A (en) | HETEROARYL COMPOUNDS AND THEIR USES | |
| PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| CR20150524A (en) | HETEROARILO COMPOUNDS AND ITS USES | |
| EA201691582A1 (en) | NEW PHARMACEUTICAL PREPARATIONS | |
| TWD174683S (en) | Ring | |
| ECSP17015977A (en) | COMBINATION THERAPY | |
| CL2017001135A1 (en) | Enhanced antibodies against il-6 | |
| DK3362066T3 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
| CU20170018A7 (en) | RORC2 PIRROLOPIRIDINE MODULATORS REPLACED WITH METHYL AND TRIFLUOROMETILO | |
| DK3400072T3 (en) | Formulations for the treatment of bladder cancer | |
| MA44987A (en) | ENHANCED DRUG FORMULATIONS | |
| DK3578562T3 (en) | L-VALINATAMIDE BENZOXABOROL DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | |
| BR112017024908A2 (en) | therapeutic uses of 4-chloroquinurenine | |
| CO2017010621A2 (en) | Fused bicyclic compounds for the treatment of diseases | |
| FR3039396B1 (en) | BASE OF CONCENTRATED COSMETIC FORMULATION | |
| ECSP18050673A (en) | GIBERELIN FORMULATIONS IN CONCENTRATED SOLUTION | |
| CL2015001920A1 (en) | Sustained release lorazepam formulations |